The role of endothelins and their receptors in heart failure

Pharmacological Research

Volumn 43, Issue 2, 2001, Pages 111-126

  Giannessi, D ^a   Del Ry, S ^a   Vitale, R L ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Anti endothelin therapy; Endothelin; Endothelin antagonists; Heart failure; Receptors

Indexed keywords

BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST;

CLINICAL TRIAL; HEART DEVELOPMENT; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE FIBROSIS; HEMODYNAMICS; HUMAN; NEURAL CREST; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR DENSITY; REVIEW; SIGNAL TRANSDUCTION; VASOCONSTRICTION;

EID: 0034956137     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.2000.0758     Document Type: Article

References (177)

1. Epidemiology of heart failure and ventricular dysfunction
2. The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment
3. New targets for heart-failure therapy: Endothelin, inflammatory cytokines, and oxidative stress
4. Molecular and cellular mechanisms of myocardial failure
5. Mechanisms and models in heart failure. A combinatorial approach
6. Characterization of a coronary vasoconstrictor produced by cultured vascular endothelial cells
7. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
8. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes
9. The human preproendothelin-1 gene: Complete nucleotide sequence and regulation of expression
10. Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology
11. Functional analysis of the endothelin-1 gene promoter: Evidence for an endothelial cell-specific cis-acting sequence
12. Generation of endothelin
13. Endothelins
14. Endothelin-3 is a novel neuropeptide: Isolation and sequence determination of endothelin-1 and endothelin-3 in porcine brain
15. ECE-1: A membrane bound metalloprotease that catalyses the proteolytic activation of big endothelin-1
16. A fourth isoform of endothelin-converting enzyme (ECE-1) is generated from an additional promoter molecular cloning and characterization
17. Two di-leucine-based motif account for the different subcellular localizations of the human endothelin-converting enzyme (ECE-1) isoforms
18. Characterization of site-directed antisera against endothelin-converting enzymes
19. Selective upregulation of cardiac endothelin system in patients with ischemic but not idiopathic dilated cardiomyopathy
20. Endothelin-converting enzyme-2 is a membrane bound, phosphoramidon-sensitive metalloprotease with acidic ph optimum
21. Critical evaluation of endothelin assay
22. Critical factors in the radioimmunoassay of endothelin-1, endothelin-3, and big endothelin-1 in human plasma
23. Presence of immunoreactive endothelin in human plasma
24. Immunoreactive endothelin in human plasma: Marked elevation in patients in cardiogenic shock
25. Radioimmunoassay of endothelin
26. A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: Comparison of levels in patients with essential hypertension and normotensive control subjects
27. Immunoreactive endothelin in human plasma urine, milk, and saliva
28. Plasma concentration of immunoreactive-endothelin in patients with chronic renal failure treated with recombinant human erythropoietin
29. A sensitive sandwich-enzyme immunoassay for human endothelin
30. Methodological assessment of HPLC separation of endothelin isoforms in human biological samples
31. 125I-endothelin in the rat: Importance of pulmonary clearance
32. Effect of endothelin-1 in man
33. Metabolism of endothelin-1 and big endothelin-1 by recombinant neutral endopeptidase EC. 3.4.24.11
34. Clearance of circulating endothelin-1 by ET-B receptors in rats
35. Prolonged blood pressure elevation after endothelin administration in bilaterally nephrectomised rats
36. Plasma endothelin levels in patients with uraemia
37. Endothelin: New discoveries and rapid progress in the clinic
38. Cloning and expression of a cDNA encoding an endothelin receptor
39. Cloning of a cDNA encoding a non-isopeptide-selective subtype of endothelin receptor
40. Cloning and expression of human endothelin-1 receptor c-DNA
41. Molecular cloning of a non-isopeptide-selective human endothelin receptor
42. Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit
43. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor
44. Is endothelin-induced vasoconstriction mediated only by ET-A receptors in humans?
45. Characterization and localization in the human atrioventricular conducting system and myocardium
46. Characterization of endothelin-1 receptor subtypes in isolated human cardiomyocytes
47. Cloning and characterization of an endothelin-3 specific receptor (ETC receptor) from Xenopus laevis dermal melanophores
48. The discovery of endothelins
49. Endothelin antagonists
50. Cellular signaling by peptides of the endothelin gene family
51. Termination of endothelin signaling: Role of nitric oxide
52. Endothelin and increased contractility in adult rat ventricular myocytes: Role of intracellular alkalosis induced by activation of the protein kinase C-dependent Na+/H+ exchanger
53. Endothelin increases myofilament Ca2+ sensitivity in alpha toxin permeabilized rabbit mesenteric artery
54. Protein kinase C and protein tyrosine kinase activity contribute to mitogenic signaling by endothelin-1: Cross-talk between G protein-coupled receptors and pp60c-src
55. Endothelin 1, phorbol esters and phenylephrine stimulate MAP kinase activities in ventricular cardiomyocytes
56. Endothelin 1 stimulates tyrosine phosphorylation and the activities of two mitogen activated protein kinases in cultured vascular smooth muscle cells
57. Coupling of two endothelin receptor subtypes to differing signal transduction in transfected Chinese hamster ovary cells
58. Non-peptide endothelin receptor antagonists. I. Effects on binding and signal transduction on human endothelin-A and endothelin-B receptors
59. Endothelin-1 (ET-1)-induced contraction in rat isolated trachea: Involvement of ET-A and ET-B receptors and multiple signal transduction systems
60. Characterization of endothelin receptors mediating contraction of rabbit saphenous vein
61. Role and mechanism of endothelin-B receptors in mediating ET-1 induced vasoconstriction in pig skin
62. Endothelins: Multifunctional renal peptides
63. Regulation of endothelin receptors by nitric oxide in cultured rat vascular smooth muscle cells
64. Specific receptor for endothelin in cultured rat cardiocytes
65. Endothelin as a regulator of cardiovascular function in health and disease
66. Positive inotropic action of novel vasoconstrictor peptide endothelin on guinea pig atria
67. Lethal ischaemia due to intracoronary endothelin in pigs
68. Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries
69. Both ET-A and ET-B receptors mediate contraction to endothelin-1 in human blood vessels
70. Endothelins contract guinea-pig pulmonary artery and enhance its adrenergic response via ET(A) receptors
71. Role of cAMP and calcium influx in endothelin-1 induced ANP release in rat cardiomyocytes
72. Effects of endothelin-1 on endothelial cells in the porcine coronary artery
73. Autocrine role for the endothelin-B receptor in the secretion of adrenomedullin
74. Polar secretion of endothelin-1 by cultured endothelial cells
75. The endothelin system in cardiovascular physiology and pathophysiology
76. Contribution of endogenous generation of endothelin-1 to basal vascular tone
77. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in man
78. Endothelin-1 and its mRNA in the wall layers of human arteries ex vivo
79. Aortic arch malformations and ventricular septal defect in mice deficient in endothelin-1
80. Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice
81. Role of endothelin-1/endothelin-A receptor-mediated signaling pathway in the aortic arch patterning in mice
82. Dual genetic pathways of endothelin-mediated intercellular signaling revealed by targeted disruption of endothelin converting enzyme-1 gene
83. Expression of B-type endothelin receptor gene during neural development
84. Ontogeny of endothelins-1 and -3, their receptors, and endothelin converting enzyme-1 in the early human embryo
85. Localization of endothelin binding sites and endothelin-like immunoreactivity in human fetal heart
86. Evidence for an effector role of endothelin in closure of the ductus arteriosus at birth
87. Control of the ductus arteriosus - A new function for cytochrome P450, endothelin and nitric oxide
88. 2 constriction but not closure of ductus arteriosus
89. Plasma endothelin levels in healthy children: High values in early infancy
90. Circulating levels of endothelin and atrial natriuretic factor during postnatal life
91. Circulating endothelin in children with congenital heart disease
92. Plasma endothelin-1 concentrations at different ages during infancy and childhood
93. Plasma endothelin-1 in patients with left-to-right shunt
94. Coronary vasoconstriction mediated by endothelin-1 in neonates. Reversal by nitroglycerin
95. High density of endothelin binding sites in the hearts of infants and children
96. Endothelins and cardiac hypertrophy
97. Pathophysiology of circulatory failure
98. Role of endothelin-1 in myocardial failure
99. Endothelin-1 in heart failure: A new therapeutic target?
100. Heart failure and endothelin receptor antagonists
101. Endothelin in chronic heart failure: Current position and future prospects
102. Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells
103. Cardiorenal actions of endothelin, part 1: Effects of converting enzyme inhibition
104. Characterization of endothelin-1 stimulation of catecholamine release from adrenal chromaffin cells
105. Cellular mechanisms of endothelin-1 release by angiotensin and vasopressin
106. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype
107. Endothelins in the kidney: Physiology and pathophysiology
108. Endothelin has biological actions at pathophysiological concentrations
109. Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium
110. Endothelin is a potent mitogen for rat vascular smooth muscle cells
111. Endothelin-1 potentiates human smooth muscle cell growth to PDGF
112. A novel vasoactive peptide endothelin stimulates mitogenesis through inositol lipid turnover in swiss 3T3 fibroblast
113. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes
114. Endothelin stimulates hypertrophy and contractility of neonatal rat cardiac myocytes in a serum-free medium
115. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy
116. Control of cardiac gene expression by mechanical stress
117. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes
118. Mechanical stretch rapidly activates multiple signal transduction pathways in cardiac myocytes: Potential involvement of an autocrine/paracrine mechanism
119. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro
120. Role of the stress-activated protein kinases in endothelin-induced cardiomyocyte hypertrophy
121. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblast by blocking endothelin-1 gene expression
122. Plasma endothelin-1 levels in idiopathic dilated cardiomyopathy
123. Plasma endothelin in chronic heart failure
124. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure
125. Increased plasma concentrations of endothelin in chronic heart failure in humans
126. Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation
127. Elevated endothelin-1 in heart failure and loss of normal response to postural change
128. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension
129. Plasma endothelin and pulmonary pressures in patients with congestive heart failure
130. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure
131. Endothelin in human congestive heart failure
132. Neurohormonal markers of clinical outcome in cardiovascular disease: Is endothelin the best one?
133. Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction
134. Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: Increase in endothelin-1 production in the heart and beneficial effect of endothelin-A receptor antagonist on survival and cardiac function
135. Expression of endothelin-1, ET-A and ET-B receptors, and ECE and distribution of endothelin-1 in failing rat heart
136. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure
137. Direct enzyme immunometric measurement of plasma big endothelin-1 concentrations and correlation with indicators of left ventricular function
138. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure
139. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart
140. Coordinated upregulation of the cardiac endothelin system in a rat model of heart failure
141. Endothelin receptors in the failing and nonfailing human heart
142. Endothelin and cardiac natriuretic peptides in heart failure
143. Role of ET-B receptors in local clearance of endothelin-1 in rat heart: Studies with the antagonist PD 155080 and BQ-788
144. Overview: Reduced sensitivity of vascular response to endothelin
145. Angiotensin II up-regulates the expression of type A endothelin receptor in human vascular smooth muscle cells
146. cAMP induces up-regulation of ETA receptor mRNA and increases responsiveness to endothelin-1 of rat aortic smooth muscle cells in primary culture
147. Regulation of endothelin receptors by nitric oxide in cultured rat vascular smooth muscle cells
148. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide
149. Molecular forms of atrial natriuretic factor in normal and failing human myocardium
150. Natriuretic peptide system in human heart failure
151. Rapid transcriptional activation, and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload
152. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure
153. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
154. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure
155. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Beneficial effects on left ventricular and myocyte function
156. Altered expression of isoforms of myosin heavy chain mRNA in the failing rat heart is ameliorated by chronic treatment with an endothelin receptor antagonist
157. Chronic oral endothelin type A receptor antagonism in experimental heart failure
158. Beneficial effects of long-term selective endothelin type A receptor blockade in canine experimental heart failure
159. The effects of endothelin-A receptor blockade during the progression of pacing-induced congestive heart failure
160. Comparison of the acute effects of a selective endothelin ET-A and a mixed ET-A/ET-B receptor antagonist in heart failure
161. Role of endogenous endothelin in chronic heart failure: Effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling
162. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction
163. Acute effects of an endothelin-1 receptor antagonist bosentan at different stages of heart failure in conscious dogs
164. Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure
165. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ET-A receptor blockade in chronic heart failure patients treated with ACE inhibitors
166. Short-term haemodynamic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure
167. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure
168. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans
169. Endothelin antagonism with bosentan: A review of potential applications
170. Multicenter, double-blind, placebo-controlled study on long-term endothelin blockade with bosentan in chronic heart failure - Results of the REACH-1 trial
171. Long-term, open-label experience with an endothelin receptor antagonist, bosentan, in patients with severe chronic heart failure
172. Endothelin and endothelin antagonists in hypertension
173. Endothelin B receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction
174. Venous endothelin receptor function in patients with chronic heart failure
175. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
176. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure